EverCommerce Scales Health IT Footprint as EverHealth Scribe Gains Momentum
Key Takeaways
- EverCommerce reported a 5.2% revenue increase in Q4 2025, driven by its EverHealth division and the successful rollout of the AI-powered EverHealth Scribe.
- The company is pivoting toward higher-margin subscription models, achieving a 29.2% EBITDA margin while serving over 745,000 customers.
Mentioned
Key Intelligence
Key Facts
- 1Q4 2025 revenue reached $151.2 million, up 5.2% year-over-year.
- 2Adjusted EBITDA margin stood at 29.2% for the quarter and 30.7% for the full year.
- 3Subscription and transaction revenue accounted for $144.1 million of total quarterly revenue.
- 4EverCommerce repurchased 8.2 million shares in 2025 for a total investment of $85 million.
- 5The company serves over 745,000 customers, with 95% of revenue coming from EverHealth and EverPro.
- 6Net leverage was reported at 2.2 times with $527 million in total debt outstanding.
EverCommerce
Company- Ticker
- EVCM
- Revenue (Q4)
- $151.2M
- Customers
- 745,000+
- EBITDA Margin
- 30.7%
A leading provider of vertical SaaS solutions for service-based businesses, specializing in health IT, home services, and professional services.
Analysis
EverCommerce (EVCM) has demonstrated significant resilience and strategic evolution in the highly fragmented Health IT and service commerce sectors, according to its Q4 2025 earnings report. The company posted quarterly revenue of $151.2 million, a 5.2% year-over-year increase that exceeded the midpoint of its previous guidance. This growth is anchored by the EverHealth division, which, alongside the EverPro segment, accounts for approximately 95% of the company's consolidated revenue. The results underscore a successful transition toward a subscription-heavy revenue model, with subscription and transaction revenue reaching $144.1 million for the quarter.
A critical driver for EverCommerce’s future growth in the healthcare space is the launch and integration of EverHealth Scribe. This AI-powered ambient documentation tool is designed to alleviate the administrative burden on clinicians—a primary cause of burnout in the medical profession. By automating clinical notes and documentation, EverHealth Scribe positions the company to compete more effectively against larger enterprise health tech players by offering a specialized, integrated solution for small-to-medium-sized (SME) medical practices. This move into AI-driven clinical workflow tools reflects a broader industry trend where SaaS providers are moving beyond simple practice management to become essential clinical partners.
EverCommerce reported an adjusted gross profit of $117 million, representing a robust 77.5% margin.
Financially, the company’s focus on operational efficiency is yielding tangible results. EverCommerce reported an adjusted gross profit of $117 million, representing a robust 77.5% margin. More impressively, the company achieved an adjusted EBITDA margin of 30.7% on a last-twelve-months (LTM) basis, a significant expansion of approximately 470 basis points since 2023. This margin expansion suggests that EverCommerce is successfully scaling its platform and realizing synergies from previous acquisitions, such as ZyraTalk, which has been integrated into its pro forma revenue calculations. The company’s ability to maintain high profitability while investing in R&D—evidenced by a $12.2 million increase in capitalized software investment—indicates a sustainable path for long-term innovation.
What to Watch
Despite the positive top-line and margin performance, the company is navigating a complex macroeconomic environment. Levered free cash flow for the year was $79.6 million, a decrease from the previous year, largely due to the aforementioned software investments and higher interest costs associated with its $527 million in outstanding debt. However, management remains confident in its liquidity position, ending the year with $130 million in cash and a net leverage ratio of 2.2 times. This confidence was further signaled by a massive share repurchase program, with 8.2 million shares bought back during 2025 for a total of $85 million.
Looking ahead, the market should watch for the continued adoption of the EverHealth Scribe and the company's ability to cross-sell its expanded AI suite across its 745,000-strong customer base. While the broader retail and real estate sectors (represented by peers like Ulta Beauty and BGSF) show mixed signals—with Ulta seeing strength in wellness but BGSF struggling with demand—EverCommerce’s focus on essential healthcare services provides a defensive moat. The primary challenge will be maintaining growth rates in the mid-single digits while continuing to expand margins in a competitive Health IT landscape.